Browse > Article
http://dx.doi.org/10.3347/kjp.2015.53.4.385

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite  

Sadeghi, Somayeh (Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran)
Seyed, Negar (Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran)
Etemadzadeh, Mohammad-Hossein (Department of Virology, Pasteur Institute of Iran)
Abediankenari, Saeid (Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Rafati, Sima (Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran)
Taheri, Tahereh (Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran)
Publication Information
Parasites, Hosts and Diseases / v.53, no.4, 2015 , pp. 385-394 More about this Journal
Abstract
Leishmaniasis is a worldwide uncontrolled parasitic disease due to the lack of effective drug and vaccine. To speed up effective drug development, we need powerful methods to rapidly assess drug effectiveness against the intracellular form of Leishmania in high throughput assays. Reporter gene technology has proven to be an excellent tool for drug screening in vitro. The effects of reporter proteins on parasite infectivity should be identified both in vitro and in vivo. In this research, we initially compared the infectivity rate of recombinant Leishmania major expressing stably enhanced green fluorescent protein (EGFP) alone or EGFP-luciferase (EGFP-LUC) with the wild-type strain. Next, we evaluated the sensitivity of these parasites to amphotericin B (AmB) as a standard drug in 2 parasitic phases, promastigote and amastigote. This comparison was made by MTT and nitric oxide (NO) assay and by quantifying the specific signals derived from reporter genes like EGFP intensity and luciferase activity. To study the amastigote form, both B10R and THP-1 macrophage cell lines were infected in the stationary phase and were exposed to AmB at different time points. Our results clearly revealed that the 3 parasite lines had similar in vitro infectivity rates with comparable parasite-induced levels of NO following interferon-${\gamma}$/lipopolysaccharide induction. Based on our results we proposed the more reporter gene, the faster and more sensitive evaluation of the drug efficiency.
Keywords
Leishmania major; EGFP; luciferase; amphotericin B; MTT; nitric oxide;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, Team WLC. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.   DOI
2 Papadopoulou B, Huang XF, Boucher N, McNicoll F. Stage-specific regulation of gene expression in Leishmania. ASM News, American Society for Microbiology 2003; 69: 282-288.
3 Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE,Wilson ME. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 2001; 167: 893-901.   DOI
4 Garg R, Gupta S, Tripathi P, Naik S, Sundar S, Dube A. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol 2005; 140: 149-156.   DOI
5 Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincendeau P, Lemesre JL. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immun 2002; 70: 3727-3735.   DOI
6 Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol 2009; 47: 412.
7 Kram D, Thale C, Kolodziej H, Kiderlen AF. Intracellular parasite kill: flow cytometry and NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation. J Immunol Methods 2008; 333: 79-88.   DOI
8 Gupta S, Sundar S, Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother 2005; 49: 3776-3783.   DOI
9 Rocha MN, Correa CM, Melo MN, Beverley SM, Martins-Filho OA, Madureira AP, Soares RP. An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein. Diagn Microbiol Infect Dis 2013; 75: 282-291.   DOI
10 Avlonitis N, Lekka E, Detsi A, Koufaki M, Calogeropoulou T, Scoulica E, Siapi E, Kyrikou I, Mavromoustakos T, Tsotinis A. Antileishmanial ring-substituted ether phospholipids. J Med Chem 2003; 46: 755-767.   DOI
11 Mikus J, Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue(R). Parasitol Int 2000; 48: 265-269.   DOI
12 Bodley AL, McGarry MW, Shapiro TA. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J Infect Dis 1995; 172: 1157-1159.   DOI
13 Croft S. In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. Parasitol Today 1986; 2: 64-69.   DOI
14 Gupta S. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res 2011; 133: 27.
15 Lang T, Goyard S, Lebastard M, Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 2005; 7: 383-392.   DOI
16 Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, Seyed N, Torkashvand F, Vaziri B, Rafati S. Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 2011; 127: 637-645.   DOI
17 Dube A, Gupta R, Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 2009; 25: 432-439.   DOI
18 Naylor LH. Reporter gene technology: the future looks bright. Biochem Pharmacol 1999; 58: 749-757.   DOI
19 Monzote L. Current treatment of leishmaniasis: a review. Open Antimicrob Agnts J 2009; 1: 9-19.
20 Gangwar S, Goyal N. Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds. Curr Microbiol 2012; 65: 696-700.   DOI
21 Wu Y, Liao Q, Yang R, Chen X, Chen X. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Res 2011; 155: 406-414.   DOI
22 Vaughan AM, Mikolajczak SA, Camargo N, Lakshmanan V, Kennedy M, Lindner SE, Miller JL, Hume JC, Kappe SH. A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol Biochem Parasitol 2012; 186: 143-147.   DOI
23 Taheri T, Saberi Nik H, Seyed N, Doustdari F, Etemadzadeh MH, Torkashvand F, Rafati S. Generation of stable L. $major^{+EGFP-LUC }$ and simultaneous comparison between EGFP and luciferase sensitivity. Exp Parasitol 2015; 150: 44-55.   DOI
24 Ploemen IH, Prudencio M, Douradinha BG, Ramesar J, Fonager J, van Gemert G-J, Luty AJ, Hermsen CC, Sauerwein RW, Baptista FG. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One 2009; 4: e7881.   DOI
25 Jain SK, Sahu R, Walker LA, Tekwani BL. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp 2012; (70): e4054.
26 Michel G, Ferrua B, Lang T, Maddugoda MP, Munro P, Pomares C, Lemichez E, Marty P. Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl Trop Dis 2011; 5: e1323.   DOI
27 Mehta SR, Zhang X-Q, Badaro R, Spina C, Day J, Chang KP, Schooley RT. Flow cytometric screening for anti-leishmanials in a human macrophage cell line. Exp Parasitol 2010; 126: 617-620.   DOI
28 Shio MT, Olivier M. Editorial: Leishmania survival mechanisms: the role of host phosphatases. J Leukoc Biol 2010; 88: 1-3.   DOI
29 Balestieri F, Queiroz A, Scavone C, Costa V, Barral-Netto M, Abrahamsohn IA. Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. Microb Infect 2002; 4: 23-29.   DOI
30 Pearson R, Harcus J, Symes P, Romito R, Donowitz G. Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani. J Immunol 1982; 129: 1282-86.
31 Paloque L, Vidal N, Casanova M, Dumètre A, Verhaeghe P, Parzy D, Azas N. A new, rapid and sensitive bioluminescence assay for drug screening on Leishmania. J Microbiol Methods 2013; 95: 320-323.   DOI
32 Reimao JQ, Trinconi CT, Yokoyama-Yasunaka JK, Miguel DC, Kalil SP, Uliana SR. Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool. J Microbiol Methods 2013; 93: 95-101.   DOI
33 Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 2001; 45: 1168-1173.   DOI